Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 94 articles:
HTML format



Single Articles


    November 2022
  1. KATO T, Tohi Y, Honda T, Matsuda I, et al
    A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
    Int J Urol. 2022 Nov 22. doi: 10.1111/iju.15102.
    PubMed     Abstract available


  2. ARAI M, Kosaka T, Yasumizu Y, Takeda T, et al
    Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15098.
    PubMed     Abstract available


  3. TERADA N, Sawada A, Kawanishi H, Fujimoto T, et al
    The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15097.
    PubMed     Abstract available


  4. TOBU S, Noguchi M
    Long-term outcomes of Blocksom vesicostomy for elderly patients with chronic urinary retention.
    Int J Urol. 2022;29:1357-1361.
    PubMed     Abstract available


    October 2022
  5. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy.
    Int J Urol. 2022 Oct 31. doi: 10.1111/iju.15090.
    PubMed     Abstract available


  6. SHIMBO M, Ohyama T, Endo F, Komatsu K, et al
    Simplified approach to the medial internal iliac region using a uretero-hypogastric nerve fascia development procedure for extended pelvic lymph node dissection during robot-assisted radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15082.
    PubMed     Abstract available


  7. MATSUMOTO T, Hori Y, Shiota M, Blas L, et al
    Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15078.
    PubMed     Abstract available


  8. HORI S, Nakai Y, Tachibana A, Omori C, et al
    Clinical significance of limited and extended pelvic lymph node dissection during robot-assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15075.
    PubMed     Abstract available


  9. FUKUHARA S, Nonomura N
    Editorial Comment to Sperm cryopreservation before definitive therapy for early-stage prostate cancer: A single institution experience.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15079.
    PubMed    


  10. VAN EECKE H, Devos G, Vansevenant B, Vander Stichele A, et al
    Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15066.
    PubMed     Abstract available


  11. YAMAMICHI G, Kato T, Yumiba S, Tomiyama E, et al
    Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15063.
    PubMed     Abstract available


  12. MIYOSHI Y, Kawahara T, Kuroda S, Takeshima T, et al
    Sperm cryopreservation before definitive therapy for early-stage prostate cancer: A single institution experience.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15047.
    PubMed    


  13. HINATA N, Yamaguchi R, Kusuhara Y, Kanayama H, et al
    Hinotori Surgical Robot System, a novel robot-assisted surgical platform: Preclinical and clinical evaluation.
    Int J Urol. 2022;29:1213-1220.
    PubMed     Abstract available


  14. ISHIKAWA H, Hiroshima Y, Kanematsu N, Inaniwa T, et al
    Carbon-ion radiotherapy for urological cancers.
    Int J Urol. 2022;29:1109-1119.
    PubMed     Abstract available


  15. TSUBOUCHI K, Gunge N, Tominaga K, Matsuzaki H, et al
    Efficacy of the opened legs position for protecting against postoperative rhabdomyolysis after robot-assisted radical prostatectomy: A propensity score-matched analysis of perioperative outcomes.
    Int J Urol. 2022;29:1132-1138.
    PubMed     Abstract available


  16. HAYASHI T, Hinata N
    Current status and future prospects of antibody-drug conjugates in urological malignancies.
    Int J Urol. 2022;29:1100-1108.
    PubMed     Abstract available


    September 2022
  17. YAMAMOTO Y, Ishii M, Yoshimura A, Hayashi T, et al
    Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan.
    Int J Urol. 2022 Sep 28. doi: 10.1111/iju.15052.
    PubMed     Abstract available


  18. GOTO Y
    Editorial Comment to miRNAs in prostate cancer: Intercellular and extracellular communications.
    Int J Urol. 2022 Sep 20. doi: 10.1111/iju.15058.
    PubMed    


  19. URABE F, Yamamoto Y, Kimura T
    miRNAs in prostate cancer: Intercellular and extracellular communications.
    Int J Urol. 2022 Sep 19. doi: 10.1111/iju.15043.
    PubMed     Abstract available


  20. YADAV S, Kumar A
    Editorial Comment by Dr Yadav and Dr Kumar to 'Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy'.
    Int J Urol. 2022 Sep 12. doi: 10.1111/iju.15032.
    PubMed    


  21. KOSHIRO N, Nakajima K, Oyama M, Kaneko G, et al
    Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
    Int J Urol. 2022 Sep 7. doi: 10.1111/iju.15022.
    PubMed     Abstract available


    August 2022
  22. SAKAMOTO S
    Editorial Comment on "Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naive prostate cancer in Japan: An interim analysis of the J-ROCK study".
    Int J Urol. 2022 Aug 29. doi: 10.1111/iju.15016.
    PubMed    


  23. UEMURA H, Matsumoto R, Mizokami A, Miyake H, et al
    Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naive prostate cancer in Japan: An interim analysis of the J-ROCK study.
    Int J Urol. 2022 Aug 26. doi: 10.1111/iju.14993.
    PubMed     Abstract available


  24. GOTO Y
    Editorial comment to Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15017.
    PubMed    


  25. KATO M
    Editorial comments on Patient-reported outcomes of a phase II neoadjuvant Apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15013.
    PubMed    


  26. URABE F
    Editorial Comment from Dr. Urabe to Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15011.
    PubMed    


  27. YANG X, Allen JC, Aslim EJ, Tay KJ, et al
    Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.14994.
    PubMed     Abstract available


  28. SASAKI T, Matsumoto R, Higashi S, Kato M, et al
    Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.14990.
    PubMed     Abstract available


  29. FUJIHARA A, Ukimura O
    Focal therapy of localized prostate cancer.
    Int J Urol. 2022 Aug 22. doi: 10.1111/iju.14991.
    PubMed     Abstract available


  30. HORI S, Nakai Y, Tomizawa M, Morizawa Y, et al
    Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.
    Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15003.
    PubMed     Abstract available


  31. KAWAHARA T, Miyoshi Y, Ninomiya S, Sato M, et al
    Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
    Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15008.
    PubMed     Abstract available


  32. ZHANG Y, Song XL, Yu B, Foong LC, et al
    TP53 loss-of-function causes vulnerability to autophagy inhibition in aggressive prostate cancer.
    Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15021.
    PubMed     Abstract available


    July 2022
  33. KIMURA K, Kitajima K, Kawanaka Y, Yokoyama H, et al
    Evaluation of (11) C-choline positron emission tomography/computed tomography for determining treatment response in castration-resistant prostate cancer patients.
    Int J Urol. 2022 Jul 25. doi: 10.1111/iju.14992.
    PubMed     Abstract available


  34. KATO T, Yokomizo A, Matsumoto R, Tohi Y, et al
    Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study.
    Int J Urol. 2022 Jul 19. doi: 10.1111/iju.14977.
    PubMed     Abstract available


    June 2022
  35. KASHIWAGI E, Shiota M, Naganuma H, Monji K, et al
    Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer.
    Int J Urol. 2022 Jun 18. doi: 10.1111/iju.14953.
    PubMed     Abstract available


  36. KONISHI T, Washino S, Okochi T, Miyagawa T, et al
    Combination of biparametric magnetic resonance imaging with prostate-specific antigen density to stratify the risk of significant prostate cancer: Initial biopsy and long-term follow-up results.
    Int J Urol. 2022 Jun 13. doi: 10.1111/iju.14948.
    PubMed     Abstract available


    May 2022
  37. NARITA S, Terada N, Nomura K, Sakamoto S, et al
    Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
    Int J Urol. 2022 May 25. doi: 10.1111/iju.14938.
    PubMed     Abstract available


  38. BANNO T, Nakamura K, Kaneda Y, Ozaki A, et al
    Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
    Int J Urol. 2022 May 18. doi: 10.1111/iju.14917.
    PubMed     Abstract available


  39. SEKITO T, Sadahira T
    Editorial Comment to Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
    Int J Urol. 2022 May 18. doi: 10.1111/iju.14934.
    PubMed    


  40. TAVERNA G, Grizzi F, Tidu L, Bax C, et al
    Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples.
    Int J Urol. 2022 May 9. doi: 10.1111/iju.14912.
    PubMed     Abstract available


    April 2022
  41. FUJITA K, Matsushita M, Banno E, De Velasco MA, et al
    Gut microbiome and prostate cancer.
    Int J Urol. 2022 Apr 6. doi: 10.1111/iju.14894.
    PubMed     Abstract available


  42. ZANG Z, Wang Z, Chiong E
    Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-c
    Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14891.
    PubMed    


  43. KATO M
    Editorial Comment to Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
    Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14890.
    PubMed    


    March 2022
  44. KAMITANI N, Miyaji Y, Tamada T, Yoden E, et al
    Feasibility of magnetic resonance imaging-ultrasound guided high-dose-rate brachytherapy for localized prostate cancer: Preliminary results from a prospective study.
    Int J Urol. 2022 Mar 30. doi: 10.1111/iju.14880.
    PubMed     Abstract available


  45. SHIOTA M
    Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2022 Mar 16. doi: 10.1111/iju.14864.
    PubMed    


  46. UEMURA H, Arai G, Uemura H, Suzuki H, et al
    Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III
    Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14843.
    PubMed     Abstract available


  47. SASAKI D, Hatakeyama S, Tanaka T, Okamoto T, et al
    Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
    Int J Urol. 2022 Mar 13. doi: 10.1111/iju.14860.
    PubMed    


  48. NARITA T, Hatakeyama S, Ohyama C
    Editorial Comment to Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Int J Urol. 2022 Mar 1. doi: 10.1111/iju.14849.
    PubMed    


    February 2022
  49. QIAN Y, Liu X, Feng Y, Li X, et al
    Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
    Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14830.
    PubMed     Abstract available


  50. TAMURA K, Matsushita Y, Watanabe H, Motoyama D, et al
    Limited impact of erectile function on health-related quality of life in Japanese men undergoing robot-assisted radical prostatectomy.
    Int J Urol. 2022 Feb 17. doi: 10.1111/iju.14826.
    PubMed     Abstract available


  51. LEE W, Lim B, Kyung YS, Kim CS, et al
    Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Int J Urol. 2022 Feb 8. doi: 10.1111/iju.14799.
    PubMed     Abstract available


  52. TANAKA T, Hatakeyama S, Noro D, Togashi K, et al
    Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2022 Feb 7. doi: 10.1111/iju.14817.
    PubMed    


    January 2022
  53. YANG Y, Liu Z, Wang Q, Chang K, et al
    Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.
    Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14801.
    PubMed     Abstract available


  54. BLAS L, Shiota M, Nagakawa S, Tsukahara S, et al
    Validation of models predicting lymph node involvement probability in patients with prostate cancer.
    Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14802.
    PubMed     Abstract available


  55. NAGUMO Y, Onozawa M, Kojima T, Terada N, et al
    Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
    Int J Urol. 2022 Jan 25. doi: 10.1111/iju.14793.
    PubMed     Abstract available


  56. MOROZUMI K, Mitsuzuka K, Narita S, Takahashi M, et al
    Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score >/=8.
    Int J Urol. 2022 Jan 18. doi: 10.1111/iju.14781.
    PubMed     Abstract available


  57. HASEGAWA M, Yamada K, Shigeta K, Yuzuriha S, et al
    How long should urologists observe patients with prostate cancer after radical prostatectomy? Weibull analysis.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14774.
    PubMed     Abstract available


  58. YAMASHITA S, Kawabata H, Deguchi R, Ueda Y, et al
    Myosteatosis as a novel predictor of urinary incontinence after robot-assisted radical prostatectomy.
    Int J Urol. 2022;29:34-40.
    PubMed     Abstract available


    December 2021
  59. TAKAHARA K, Naiki T, Ito T, Nakane K, et al
    Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
    Int J Urol. 2021 Dec 4. doi: 10.1111/iju.14754.
    PubMed     Abstract available


    November 2021
  60. WURNSCHIMMEL C, Wenzel M, Chierigo F, Simone Flammia R, et al
    Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 17. doi: 10.1111/iju.14743.
    PubMed    


  61. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer.
    Int J Urol. 2021 Nov 11. doi: 10.1111/iju.14738.
    PubMed     Abstract available


  62. SO WZ, Wang Z, Tiong HY
    Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 5. doi: 10.1111/iju.14741.
    PubMed    


    October 2021
  63. YUASA T
    Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Oct 6. doi: 10.1111/iju.14725.
    PubMed    


  64. AKAKURA K
    Editorial Comment to External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Oct 4. doi: 10.1111/iju.14723.
    PubMed    


  65. YAMAMOTO S
    Editorial Comment to Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1045-1046.
    PubMed    


  66. FUKUNAGA A, Maejima A, Shinoda Y, Matsui Y, et al
    Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1039-1045.
    PubMed     Abstract available


  67. TEO XL, Lim SK
    Targeting the vessels first: A modified surgical technique for prostatic paraganglioma.
    Int J Urol. 2021;28:1073-1074.
    PubMed    


    September 2021
  68. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14701.
    PubMed     Abstract available


  69. SHIOTA M, Blas L, Kobayashi S, Matsumoto T, et al
    Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14702.
    PubMed     Abstract available


  70. KADONO Y
    Editorial Comment to Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14690.
    PubMed    


  71. COLARIETI A, Thiruchelvam N, Barrett T
    Evaluation of image-based prognostic parameters of post-prostatectomy urinary incontinence: A literature review.
    Int J Urol. 2021;28:890-897.
    PubMed     Abstract available


    August 2021
  72. MAESAKA F, Tanaka N, Nakai Y, Asakawa I, et al
    Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Aug 10. doi: 10.1111/iju.14667.
    PubMed     Abstract available


  73. NAKAI Y, Tanaka N, Fujii T, Miyake M, et al
    Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015.
    Int J Urol. 2021 Aug 5. doi: 10.1111/iju.14666.
    PubMed     Abstract available


    July 2021
  74. MIYAMOTO S, Goto K, Honda Y, Terada H, et al
    Tumor contact length of prostate cancer determined by a three-dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence.
    Int J Urol. 2021 Jul 5. doi: 10.1111/iju.14633.
    PubMed     Abstract available


  75. SHIGEMURA K, Fujisawa M
    Prevention and management of infectious complications in prostate biopsy: A review.
    Int J Urol. 2021;28:714-719.
    PubMed     Abstract available


    June 2021
  76. SUGIHARA T
    Editorial Comment to Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 Jun 24. doi: 10.1111/iju.14620.
    PubMed    


  77. NAKAJIMA K, Mizokami A, Matsuyama H, Ichikawa T, et al
    Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
    Int J Urol. 2021 Jun 19. doi: 10.1111/iju.14614.
    PubMed     Abstract available


  78. ANDELA CD, Matte R, Jazet IM, Zonneveld WC, et al
    Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review.
    Int J Urol. 2021 Jun 14. doi: 10.1111/iju.14596.
    PubMed     Abstract available


  79. KIMURA Y, Honda M, Teraoka S, Yumioka T, et al
    Impact of penile rehabilitation with phosphodiesterase-5 inhibitors on recovery of erectile function in patients undergoing robot-assisted radical prostatectomy: A propensity score-matched analysis.
    Int J Urol. 2021;28:637-642.
    PubMed     Abstract available


  80. TAGUCHI S, Morikawa T, Shibahara J, Fukuhara H, et al
    Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review.
    Int J Urol. 2021;28:614-621.
    PubMed     Abstract available


    May 2021
  81. STOLZENBACH LF, Deuker M, Colla-Ruvolo C, Nocera L, et al
    Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
    Int J Urol. 2021 May 28. doi: 10.1111/iju.14586.
    PubMed     Abstract available


  82. CHIKAMATSU S, Shiota M, Onozawa M, Hinotsu S, et al
    Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
    Int J Urol. 2021 May 24. doi: 10.1111/iju.14605.
    PubMed     Abstract available


  83. INOUE T, Yoshimura K, Terada N, Tsukino H, et al
    Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
    Int J Urol. 2021 May 18. doi: 10.1111/iju.14590.
    PubMed     Abstract available


  84. WURNSCHIMMEL C, Wenzel M, Colla Ruvolo C, Nocera L, et al
    Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 May 15. doi: 10.1111/iju.14595.
    PubMed     Abstract available


  85. IGUCHI T, Kimura G, Fukasawa S, Suzuki H, et al
    Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Int J Urol. 2021 May 6. doi: 10.1111/iju.14568.
    PubMed     Abstract available


  86. CLAPS F, Ramirez-Backhaus M, Mir Maresma MC, Gomez-Ferrer A, et al
    Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:566-572.
    PubMed     Abstract available


  87. MATTI B, Zargar-Shoshtari K
    Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population.
    Int J Urol. 2021;28:578-583.
    PubMed     Abstract available


  88. LOW AW, Chen K, Tan YG, Ng TK, et al
    Ambulatory robot-assisted laparoscopic radical prostatectomy with extended recovery by total extraperitoneal approach.
    Int J Urol. 2021;28:561-565.
    PubMed     Abstract available


    April 2021
  89. YOSHIDA S, Fujii Y
    Editorial Comment to Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14578.
    PubMed    


  90. AIZAWA R, Takayama K, Nakamura K, Ogata T, et al
    Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 2. doi: 10.1111/iju.14567.
    PubMed     Abstract available


  91. TATENUMA T, Makiyama K, Ito Y, Muraoka K, et al
    Correlation of urinary loss rate after catheter removal and long-term urinary continence after robot-assisted laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:440-443.
    PubMed     Abstract available


  92. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Comprehensive approach for preserving cavernous nerves and erectile function after radical prostatectomy in the era of robotic surgery.
    Int J Urol. 2021;28:360-368.
    PubMed     Abstract available


    February 2021
  93. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
    Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
    Int J Urol. 2021;28:225-240.
    PubMed     Abstract available


    January 2021
  94. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
    Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
    Int J Urol. 2021;28:47-52.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: